In direct compression and wet granulation campaigns for 100 mg and 200 mg veterinary tablets, Qiangzhuang Powder is first screened through a 425 µm stainless steel vibratory sieve and pre-blended with microcrystalline cellulose in a 1:1 ratio before addition of the remaining diluent. When the incoming active fraction has a Carr index above 25.0 or a Hausner ratio above 1.35, direct compression is not used; instead, the active is wet-granulated with povidone K30 at 3.0–5.0% w/w solids and purified water in a high-shear mixer at impeller speeds of 300–500 rpm. The granulation is dried in a fluid bed at inlet air temperature of 65–70 °C, product temperature of 32–38 °C, and air flow of 1.5–2.0 m/s until loss on drying is 1.5–2.5%. Dried granules are screened through an 850 µm mesh and blended with crospovidone at 3.0–5.0% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.0% w/w for 3–5 min at 12 rpm in a bin blender. Tablet compression on a 39-station rotary press equipped with 9 mm round concave B-tooling is run at 40–55 rpm, with pre-compression force of 3–6 kN and main compression force of 8–18 kN to produce tablets of 70–110 N hardness. Friability is kept not more than 1.0% using USP <1216>, disintegration is controlled to not more than 15 min using USP <701> in 0.1 N HCl at 37 ± 0.5 °C, and content uniformity for 10 tablets is required to fall within 95.0–105.0% of label claim with relative standard deviation not more than 5.0%. Ejection forces above 900 N indicate sticking due to inadequate lubricant coverage or excessive moisture; in such cases, batch records should trigger re-lubrication with 0.25% w/w additional sodium stearyl fumarate and a 2–3 min blend. If the tablet is moisture-sensitive, a film coating of hypromellose 2910 at 3.0–4.0% weight gain is applied in a side-vented pan at inlet temperature 55–65 °C, bed temperature 38–45 °C, and spray rate 8–12 g/min per kilogram of tablets. The finished tablets are packed into Alu-Alu blisters with a barrier film having water vapour transmission rate below 0.1 g/m²/day at 40 °C/75% RH.

What Limits Terminal Sterilization of Injectable Solutions Containing Micronized Qiangzhuang Powder?

For injectable presentations, the aseptic or terminal sterilization route is selected only after a forced degradation study establishes the thermal and hydrolytic stability of the dissolved Qiangzhuang Powder fraction. Aqueous formulations at 10–100 mg/mL active fraction are prepared in Water for Injection and adjusted to pH 4.5–7.0 with 10–25 mM citrate or phosphate buffer, because phosphate-buffered solutions above pH 7.5 accelerate base-catalyzed degradation in many veterinary actives. Osmolality is adjusted to 285–310 mOsm/kg using sodium chloride or dextrose. If no degradation greater than 2.0% is observed after 15 min at 121 °C, terminal sterilization is performed in a rotary autoclave at minimum F₀ = 8.0 and maximum F₀ = 30.0, with hold time at 121 °C for 15 min. If the active is heat-labile, the bulk solution is filtered through two 0.22 µm PVDF filters in series inside a Grade A laminar airflow zone, then aseptically filled into sterile Type I glass vials or pre-sterilized cyclic olefin copolymer syringes. For suspension injections, the micronized active is wet-milled in a colloid mill to D₁₀ = 1.5 µm, D₅₀ = 3.5 µm, and D₉₀ = 8.0 µm, with particle size determined by laser diffraction according to ISO 13320-1:2020; a wetting agent of polysorbate 80 at 0.1–0.2% w/v is added to prevent agglomeration. Endotoxin content is limited to not more than 0.5 EU/mg using EP 2.6.14, sterility is tested using EP 2.6.1, and sub-visible particulate matter is controlled according to USP <788> for small-volume parenterals. Residual oxygen in the headspace is reduced to below 1.0% by nitrogen overlay, and antioxidant such as sodium metabisulfite at 0.05–0.1% w/v may be included only when the target species has no documented sulfite sensitivity. For lyophilized vials, the solution is filled at 5.0 mL per vial, frozen to -40 °C at 1 °C/min, primary-dried at -20 °C and 0.20 mbar for 36–48 h, and secondary-dried at 25 °C for 6–12 h until Karl Fischer residual moisture is below 1.0% w/w. Processing equipment consists of 316L stainless steel vessels with 0.2 µm vent filters, cleaned by clean-in-place cycles at 85 °C for 20 min and sterilized-in-place at 121 °C for 30 min. Published data for this specific powder in injectable form is limited; therefore the parameters above are conventional injectable veterinary manufacturing ranges, and a formulation-specific matrix study is required before batch release.

On automatic capsule filling lines, Qiangzhuang Powder formulations are filled into size 3 or size 4 hard gelatin or hypromellose capsules at total fill weights of 100–250 mg, with active content per capsule as low as 5.0 mg. Because low-dose active fractions segregate when the excipient particle size differential exceeds 100 µm, the filler system uses lactose monohydrate with D₅₀ = 80–120 µm and pregelatinized starch with D₅₀ = 50–80 µm, both screened through 250 µm mesh before blending. Colloidal silicon dioxide at 0.5–1.0% w/w is used as a glidant, and sodium stearyl fumarate at 1.0–2.0% w/w replaces magnesium stearate where hygroscopic shell embrittlement is a concern. The blend is prepared in a 600 L bin blender at 12 rpm for 10 min, and blend uniformity is sampled at 10 points with acceptance of 95.0–105.0% label claim and RSD not more than 5.0%. A dosator-type capsule machine is configured with a 6 mm nozzle diameter, powder bed height of 30–40 mm, tamping pin stroke of 20 mm, and machine speed up to 60,000 capsules/h; fill weight acceptance is ±4.0% from target. The filling area is maintained at 40–50% RH and 20–25 °C, with capsule shell moisture at 13–16% w/w for gelatin; below 30% RH shell brittleness increases and above 60% RH softened shells deform on the closing station. Disintegration is tested using USP <701> with acceptance of not more than 15 min in 0.1 N HCl at 37 ± 0.5 °C. For moisture-sensitive actives, hypromellose capsules with water vapour transmission rate below 0.5 g/m²/day at 40 °C/75% RH are used, and a molecular sieve canister is placed in the bulk pack to maintain headspace humidity below 30% RH. Torque readings on the capsule machine dosing disk are monitored; a deviation above 1.5 N·m indicates powder adhesion to dosator surfaces, which requires reducing ambient humidity to 40–45% RH or increasing glidant concentration to 1.0% w/w.

Drinking Water Medication: Sedimentation, pH Stability, and Dispersion Faults

Water-dispersible powder formulations of Qiangzhuang Powder are blended from the active fraction, lactose monohydrate, citric acid, sodium bicarbonate, and polyvinylpyrrolidone K25 as a dispersant. The dry blend is intended for reconstitution at 0.5–2.0 g/L in drinking water, producing a target active concentration of 50–200 mg/L depending on species and body weight. Particle size of the active fraction is maintained at D₅₀ = 20–50 µm and D₉₀ ≤ 150 µm using laser diffraction according to ISO 13320-1:2020; particles above 150 µm settle too quickly in standing troughs, and particles below 5 µm create persistent foam that reduces water intake. Polysorbate 80 at 0.05–0.2% w/w is added to lower the contact angle and reduce surface tension below 45 mN/m at 25 °C; without this wetting agent, hydrophobic active particles float at the meniscus and produce uneven dosing. Dissolution or dispersion time is tested by adding the sachet content to 10 L of water at 10 °C with gentle stirring; complete visual dispersion is required within 3 min. Hard water containing 300 mg/L as CaCO₃ can reduce wetting efficiency by up to 20% unless citrate buffer is included at 0.5–2.0% w/w to chelate calcium and magnesium ions. The drinking water pH after reconstitution must remain between 5.5 and 7.5 for chemically labile actives; if the active is acid-stable, citric acid lowers pH to 3.5–5.0 and improves microbial stability during a 24 h administration window. Sedimentation volume after 4 h is measured with a 1 L graduated cylinder; settled solids must be below 1.0 mL/L, and the redispersibility test must restore the suspension within 30 s of inversion. The powder is filled into laminated foil sachets with moisture barrier below 0.1 g/m²/day at 40 °C/75% RH, and bulk density is controlled between 0.45 g/mL and 0.65 g/mL for volumetric dosing spoons. On farm mixing tanks, recirculation at 0.5–1.0 m/s is required to eliminate dead zones in corners; a 2.0 m/s recirculation rate increases foam and air embolism in drinking lines.

When Binder Viscosity Exceeds 250 mPa·s During Wet Granulation of Soluble Granules

For oral granule presentations and sachet dosing, Qiangzhuang Powder is wet-granulated in a high-shear mixer with an aqueous binder system in which binder viscosity is controlled below 250 mPa·s at 25 °C; higher viscosity produces oversized granules above 850 µm, retards dissolution, and causes under-dosing in drinking water or milk replacer. A typical binder is povidone K30 at 3.0–5.0% w/w solids or pregelatinized starch at 5.0–8.0% w/w solids, with granulation fluid added at 25–35% w/w of the dry blend. High-shear processing uses an impeller speed of 300–500 rpm and a chopper speed of 1500–3000 rpm; the endpoint is reached at torque values of 10–15 N·m or power consumption of 6–8 kW for a 100 kg batch. The wet mass is passed through a 2.0 mm screen and dried in a fluid bed with inlet air at 60–70 °C, product temperature of 35–42 °C, and air velocity of 1.0–1.5 m/s until loss on drying is 1.0–2.0%. Dried granules are screened to 250–850 µm; the fraction above 850 µm is milled and re-screened, while the fraction below 250 µm is recycled into the next granulation at not more than 20% w/w to prevent overwetting. Granule flow is measured by Carr index, which must be 20 or less, and Hausner ratio, which must be 1.25 or less; angle of repose is controlled between 25° and 35° for reproducible sachet filling. Sachet fill weights of 1.0–5.0 g are sealed at 150–175 °C for 0.5–1.0 s using laminated foil with a 40 µm aluminium layer; seal strength is tested to not less than 25 N/15 mm. Dissolution testing of the finished granules uses USP <711> apparatus 2 at 50 rpm in 900 mL water at 37 °C; not less than 80% of the labeled active is released within 10 min. If binder viscosity exceeds 250 mPa·s, the correction is to dilute the granulation fluid with ethanol-water 1:1 to reduce surface tension and viscosity, then reprocess the batch; this is recorded as a process deviation and requires revalidation of blend uniformity and dissolution.

In medicated feed premix manufacture, Qiangzhuang Powder is incorporated at active concentrations between 2.0% w/w and 10.0% w/w using a geometric dilution sequence that begins with a 1:3 active-to-carrier blend before the 1:10 stage. The carrier is ground corn cob or rice hulls with moisture of 8.0–12.0% and particle size of 300–600 µm; mineral oil at 0.5–1.0% w/w is added to reduce dust and improve adhesion of the active to carrier surfaces. Mixing is performed in a horizontal ribbon blender filled to 60–80% of gross capacity, with a ribbon tip speed of 2.5–3.5 m/s and a total mixing time of 10–20 min after the final addition. A sampling protocol of 10 randomly selected points with 50 g samples is used; the active assay relative standard deviation must be not more than 5.0% using high-performance liquid chromatography calibrated against a Qiangzhuang Powder working standard. Geometric dilution proceeds as follows: the active is mixed 1:3 with carrier for 5 min, then additional carrier is added to reach 1:10 and mixed for 10 min, and the remaining carrier is added to reach final concentration and mixed for 15 min. The finished premix is then incorporated into final feed at 0.5–5.0 kg per tonne, depending on target dose; final feed mixing in a vertical twin-screw mixer at 60 rpm for 5 min is expected to give a coefficient of variation not more than 10%. Carryover into the next non-medicated batch is controlled by a 20 kg ground corn flush after each medicated batch; residual active in the flush material must be below 10 mg/kg on a dry-matter basis. All equipment contact surfaces are 316L stainless steel or food-grade polyethylene to avoid metal-catalysed degradation of the active fraction. Specific published batch data for Qiangzhuang Powder in this application is limited; the ranges above are standard medicated premix manufacturing controls, and each facility must validate recovery and carryover with the specific batch of API and carrier.

Oral Drench Formulations Require Viscosity Below 20 mPa·s at 20°C

For oral solution and drench presentations, Qiangzhuang Powder is dissolved or finely suspended in a co-solvent system of propylene glycol 10–30% v/v, glycerin 5–15% v/v, and purified water q.s. to a final active concentration of 25–100 mg/mL. Viscosity is measured by rotational viscometer with a concentric cylinder spindle at 20 °C and 100 rpm; values must remain below 20 mPa·s because dosing guns calibrated to deliver 1.0–10.0 mL per animal require a viscosity-dependent accuracy of ±2.0% of the set volume. The pH is adjusted to 4.0–6.0 with 5–20 mM citrate buffer; below pH 3.0, repeated contact with stainless steel dosing nozzles may cause corrosion, and above pH 7.5, the active fraction may precipitate or degrade through base-catalyzed mechanisms. For multidose containers, methylparaben at 0.18% w/v and propylparaben at 0.02% w/v are used as preservatives; if potassium sorbate is used instead, its concentration is maintained at 0.1–0.2% w/v and pH is kept below 5.5 to retain the active acid form. If oxygen sensitivity is identified, sodium thiosulfate at 0.1% w/v or tocopherol polyethylene glycol succinate at 0.5–1.0% w/v is added, and the headspace is flushed with nitrogen to residual oxygen below 2.0%. The bulk solution is filtered through a 10 µm polypropylene cartridge before filling; visible particulates are unacceptable, and sub-visible particulate counts are checked by light obscuration with acceptance criteria adapted from USP <788> for non-injectable liquids. Fill lines are set to 20–25 °C, and 316L stainless steel tanks are used with bottom-mounted magnetic stir bars to prevent vortex air entrainment. Storage under 25 °C/60% RH is used for long-term stability; if the active is thermolabile, storage at 2–8 °C and protection from light are required, with re-test intervals set by bracketing studies. The transition from powder API to drench solution should be confirmed by HPLC assay recovery of 98.0–102.0% of the labeled active in the finished container, with no more than 0.5% total degradation products at release.